The hidden reason cancer immunotherapy often fails
Cancer immunotherapy has been a game-changer, but many tumors still find ways to slip past the immune system. New research reveals a hidden trick: cancer cells can package the immune-blocking protein PD-L1 into tiny particles that circulate through the body and weaken immunotherapy’s impact. Scientists in Japan discovered that a little-known protein, UBL3, controls this process—and surprisingly, common cholesterol-lowering drugs called statins can shut it down.
Scientists discovered how cancer cells secretly spread immune-blocking signals using tiny vesicles filled with PD-L1. Even more surprising, widely used statins can disrupt this process, potentially making immunotherapy far more effective. Credit: Shutterstock.
#worldresearchawards #researcherawards #academicawards #scienceawards #globalresearchawards #phd #researcher #NewScientistsAwards #NSCAwards #CancerImmunotherapy #TumorMicroenvironment #ImmuneEvasion #PD1 #PDL1 #CheckpointInhibitors #CancerResistance #PrecisionOncology #ImmunoOncology #TumorHeterogeneity
Scientists discovered how cancer cells secretly spread immune-blocking signals using tiny vesicles filled with PD-L1. Even more surprising, widely used statins can disrupt this process, potentially making immunotherapy far more effective. Credit: Shutterstock.
New Scientists Awards - NOMINATION OPEN NOW!
Nomination Link: https://newscientists.net/award-nomination/?ecategory=Awards&rcategory=Awardee
Web Visitors: newscientists.net
For Enquiry: info@newscientists.net
Comments
Post a Comment